



PsychoTropical Psychopharmacology, Neuropharmacology & Toxicology Expertise

Aug 2019

Dr Ken Gillman

Convener: MAOI
International
Experts Group

Expertise in:

Psycho-
pharmacology

Serotonin toxicity

Neuroleptic
malignant
syndrome

Drug interactions

MAOIs

TCAs

SSRIs

SNRIs

Information at:

PsychoTropical.in
fo

MAOI anti-depressant drugs

Dear Colleague,

A patient who wishes to consider treatment with MAOI anti-depressant drugs has obtained this letter from my [website](#). This letter is to help you assess and advise on this request, especially because the information available in most sources is out-of-date, inaccurate, or unhelpful.

I have a number of peer-reviewed scholarly publications specifically reviewing MAOIs [1-6], and I am the convener of the respected 'MAOI International Experts Group' which provides advice to doctors who use, and wish to learn more about, MAOI drugs. My google scholar profile is here:

<http://scholar.google.com.au/citations?user=ea6KeD0AAAAJ&hl=en>

I have extensive experience of using monoamine oxidase inhibitor (MAOI) drugs (phenelzine, Nardil; tranylcypromine, Parnate; isocarboxazid, Marplan, and now the successor to selegiline, rasagiline, Azilect). These drugs are somewhat maligned and reduced knowledge and awareness of them makes many doctors shy away from using them when they would be efficacious, and sometimes lifesaving. There are several interesting stories relating to this on my website, particularly that of the famous Professor who wrote a psychopharmacology book saying they were dangerous and ineffective. He became seriously depressed himself, and after three years of unremitting illness was only made well after he was given tranylcypromine. [He re-wrote his book!](#)

Almost all experienced psycho-pharmacologists (and guidelines) accept the evidence that MAOIs are effective & potent anti-depressant drugs. They deserve to regain a more prominent place in our therapeutic armamentarium. The side effects and possible interactions of MAOIs have been much exaggerated. Tranylcypromine often has less side effects

than newer drugs. The low tyramine diet is easy and better understood than it was in the past (see the [guidelines and documentation on my website](#)).

The financial power of pharmaceutical companies, that dominate post-graduate education and have aggressively promoted the supposed advantages of newer drugs, has a detrimental effect on prescribing and has seriously unbalanced the optimal use of many medications.

If you are a doctor who uses, or would consider using, MAOI antidepressant drugs, then you may apply to join the clinicians information and support MAOI group (email me at ken.psychotropic@gmail.com). This group has access to the expert group who can answer particular questions that come up.

If you would like to look, there is much referenced information on my website, which is a world-renowned hub for information about MAOIs, and you can Skype and email me (see the website):

<https://psychotropic.info/maois/>

I am personally available for comment or advice.

Yours Sincerely,

Dr. Ken Gillman

References

1. Finberg, J. and P. Gillman, *Pharmacology of MAO-B inhibitors and the cheese reaction*, in *International Review of Neurobiology*, M. Youdim and P. Riederer, Editors. 2011, Elsevier Inc. Academic Press.: Burlington. p. 169-190.
2. Gillman, P.K., *CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity*. *Journal of Psychopharmacology*, 2011. **25**(3): p. 429-3.
3. Gillman, P.K., *Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors*. *Journal of Clinical Psychopharmacology*, 2011. **31**(1): p. 66-74.
4. Gillman, P.K., "Much ado about nothing": *monoamine oxidase inhibitors, drug interactions, and dietary tyramine*. *CNS Spectr*, 2017: p. 1-3.
5. Gillman, P.K., *A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths*. *J Neural Transm (Vienna)*, 2018. **125**(11): p. 1707-1717.
6. Gillman, P.K., S. Feinberg, and L. Fochtmann, *Revitalizing monoamine oxidase inhibitors: A call for action*. *CNS spectrums*, 2019: p. <http://dx.doi.org/10.1017/S1092852919001196>.